XXXX channel blockers for heart rate control in @entity955 complicated by @entity712 .

@entity1 @entity712 @entity713 @entity1855 @entity3988 @entity955 @entity299 @entity460 @entity551 @entity1002
OBJECTIVES: To review the safety and efficacy of @entity1855 and @entity3988 with respect to ventricular response in @entity955 ( @entity955 ) in the setting of left ventricular (LV) @entity299 . DATA SOURCES: Pertinent articles were identified through a MEDLINE search of the English language literature from 1984 to 1993, followed by a manual search of the bibliographies of pertinent articles. STUDY SELECTION: Studies selected were case reports, controlled trials, review articles and editorials. DATA EXTRACTION: Effects of @entity1855 and @entity3988 on hemodynamics, ventricular response in @entity955 , clinical parameters and mortality were reviewed. DATA SYNTHESIS: There are limited data about the effects of @entity1855 and @entity3988 on ventricular function in @entity1 with @entity712 . In vitro @entity3988 has fewer negative inotropic effects than @entity1855 . Clinically there are some reports of hemodynamic and clinical deterioration in @entity1 with significant @entity1002 given @entity1855 although most @entity1 improve with @entity1855 . There are more data concerning @entity3988 in the setting of @entity955 complicated by @entity712 . The drug does not appear to exacerbate @entity712 , although @entity551 can result. In chronic @entity955 complicated by @entity712 , there is concern that @entity3988 may increase mortality. Options for therapy are digoxin, beta-blockers and @entity713 . CONCLUSIONS: @entity460 channel blockers may have a role in the acute reduction of ventricular response in @entity1 with @entity955 complicated by @entity712 ; however, their safety in chronic heart rate control remains to be proven.
